ArticleScientific reports2026
Deciphering oxidative stress-related heterogeneity and developing a prognostic signature for colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
While recent studies have highlighted oxidative stress (OS) as a pivotal factor influencing tumor dynamics, its specific interactions within the tumor microenvironment (TME) of colorectal cancer (CRC) remain elusive. This study seeks to unveil the impact of OS on the CRC TME and to develop an advanced OS-related risk signature (OSRRS) model. We analyzed OS-related pathway activities using both single-cell and bulk RNA-seq data. An unsupervised clustering algorithm was utilized to identify OS-related subtypes. Based on genes associated with the OS pathways, we constructed an OSRRS model employing the LASSO Cox analysis. For validation, we employed quantitative real-time polymerase chain reaction (qRT-PCR) coupled with immunohistochemical (IHC) analyses on tissue microarrays (TMA) to confirm the expression of the identified gene. Examination of the single-cell RNA-seq GSE132465 dataset revealed a universal elevation in OS-associated pathway activities within malignant cells. By integrating this with the bulk RNA-seq TCGA-CRC dataset, we identified two unique OS-specific clusters. This led to the establishment of a 12-gene OSRRS using the LASSO Cox method. The robustness of our model was further verified using the GSE39582 and GSE17538 cohorts. Notably, increased expression of the UCN gene was observed in CRC specimens, as confirmed by qRT-PCR and IHC assays on TMA. In this research, we delineated two distinct subtypes of CRC associated with OS. The developed OSRRS holds promise as a candidate prognostic and stratification tool for CRC management. Collectively, these results shed light on the intricate role of OS in CRC pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.